About Reflux Pharmaceuticals Private Limited
Data last updated:
Reflux Pharmaceuticals Private Limited is a private limited company based in Thane, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 February 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U74999MH2020PTC337046. Its GSTIN is 27AAKCR0622C1ZR (Maharashtra).
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹76.76 Lakh. It is led by directors including Amit Kumar Ghosh and Sandeep Khandu Tekle.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at A Gami Industrial Park, Thane, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹20.56 Cr, a growth of 15% compared to the previous year. For the same year it recorded a net profit of ₹57.3 Lakh (net margin 2.8%) and EBITDA of ₹98.01 Lakh (EBITDA margin 4.8%). Revenue has grown at a compounded annual rate (CAGR) of 5% over three years.
The company is associated with 1 brand: Reflux Pharmaceuticals. As per MCA filings, the company has open charges of ₹8.5 Cr and satisfied charges of ₹5.18 Cr on record. The company has 1 deal on record (1 funding round), with disclosed funding of ₹7.01 Cr; the latest was in May 2023. Its 10 peer companies in the Pharma industry (API Manufacturers, Pharmaceuticals) are compared by revenue, 5 larger and 5 smaller; the largest is SBD Healthcare Private Limited with revenue of ₹20.74 Cr. The company has 4 MSME Form 1 returns on record between 2022 and 2023, listing 16 overdue payments to 4 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website refluxpharmaceuticals.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressGala No. 83 3rd Floor C – 39/A Gami Industrial Park, Ttc Industrial Area MIDC Pavane, Thane, Maharashtra, India – 400705
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Reflux Pharmaceuticals Private Limited
The main business activity of Reflux Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Reflux Pharmaceuticals Private Limited FY 2025 filings available
Reflux Pharmaceuticals Private Limited reported revenue of ₹20.56 Cr (up 15% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Reflux Pharmaceuticals Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 5% over three years, including 15% growth in the latest year. EBITDA rose 171% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Reflux Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹98.01 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹57.3 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Reflux Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 4.8% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 2.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Reflux Pharmaceuticals are in the company report.
Financial statements from FY 2020
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Reflux Pharmaceuticals Private Limited
Reflux Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| SBD Healthcare Private Limited | ₹20.74 Cr (FY 2024) | •••• | •••• | 92.0% | •••• | Ankleshwar, Gujarat, India |
| Essel Pharmaceuticals Private Limited | ₹20.71 Cr (FY 2025) | •••• | •••• | 130.0% | •••• | Kanpur, Uttar Pradesh, India |
| Medinex Laboratories Private Limited | ₹20.62 Cr (FY 2024) | •••• | •••• | -8.0% | •••• | Bhavnagar, Gujarat, India |
| Bhattacharjee Pharmaceuticals and Company Ltd | ₹20.61 Cr (FY 2024) | •••• | •••• | 13.0% | •••• | Beleghata, West Bengal, India |
| Medizest Pharmaceuticals Private Limited | ₹20.59 Cr (FY 2024) | •••• | •••• | 54.0% | •••• | Verna, Goa, India |
| Reflux Pharmaceuticals Private Limited this company | ₹20.56 Cr (FY 2025) | •••• | •••• | 15.0% | •••• | Thane, Maharashtra, India |
| Altis Finechem Private Limited | ₹20.53 Cr (FY 2025) | •••• | •••• | 62.0% | •••• | Prantij, Gujarat, India |
| Tosco Pharma Private Limited | ₹20.42 Cr (FY 2024) | •••• | •••• | 337.0% | •••• | Hyderabad, Telangana, India |
| Nizam Baba Pharmaceuticals Private Limited | ₹20.31 Cr (FY 2025) | •••• | •••• | 138.0% | •••• | Kankinara, West Bengal, India |
| Scikem Pharmaceuticals Private Limited | ₹20.26 Cr (FY 2024) | •••• | •••• | -43.0% | •••• | Hydertabad, Telangana, India |
| Tesla Chemicals Private Limited | ₹20.24 Cr (FY 2025) | •••• | •••• | -18.0% | •••• | Panoli, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Reflux Pharmaceuticals by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Reflux Pharmaceuticals Private Limited
Reflux Pharmaceuticals Private Limited is audited by Y. K. Desai & Co. for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Y. K. Desai & Co. | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Reflux Pharmaceuticals Private Limited
Reflux Pharmaceuticals has 3 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jaid Ismail Kojar Also directs: Eiko Scientific Solutions LLP, Eiko Lifesciences Limited, Techvertica Technologies Private Limited and 1 more | Nominee Director | 29 Jul 2024 | 2 Years 2 Months | Current |
| Amit Kumar Ghosh | Director | 03 Feb 2020 | 6 Years 8 Months | Current |
| Sandeep Khandu Tekle Also directs: Ghumakkad TTC Private Limited | Director | 03 Feb 2020 | 6 Years 8 Months | Current |
Ownership and Shareholding of Reflux Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Reflux Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Mar 2023 | Others | ₹8.5 Cr | Open |
| 17 Mar 2022 | Others | ₹5.18 Cr | Satisfied |
Total charge records: 2 View all charges
Deals & Funding of Reflux Pharmaceuticals Private Limited
Reflux Pharmaceuticals Private Limited has 1 deal on record (1 funding round), with disclosed funding of ₹7.01 Cr; the latest was in May 2023.
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2023 | Funding round | ₹7.01 Cr | Investors: Eiko Lifesciences Limited |
Full deal history
All 1 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
MSME Payment Delays by Reflux Pharmaceuticals Private Limited
Reflux Pharmaceuticals Private Limited has 4 MSME Form 1 returns on record between 2022 and 2023, listing 16 overdue payments to 4 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (4 of 4)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Rangoli Plastics Private Limited | •••• | •••• | •••• |
| Y. K. Desai & Co. | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 4 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Reflux Pharmaceuticals Private Limited
Reflux Pharmaceuticals operates one associated brand: Reflux Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Active pharmaceutical ingredients and intermediates are manufactured by Reflux Pharmaceuticals. | refluxpharmaceuticals.com |
Employees and EPFO Compliance at Reflux Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Reflux Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
News related to Reflux Pharmaceuticals Private Limited
Recent Activity on Reflux Pharmaceuticals Private Limited
Reflux Pharmaceuticals Private Limited has 3 board changes on record since 2020: 3 appointments. The latest: Jaid Ismail Kojar was appointed as Nominee Director on 29 Jul 2024.
Credit Ratings, Litigation & Regulatory Alerts for Reflux Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Reflux Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Reflux Pharmaceuticals Private Limited
Reflux Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAKCR0622C1ZR | Maharashtra | Active | 27 May 2020 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Reflux Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Reflux Pharmaceuticals Private Limited
Reflux Pharmaceuticals is an active private limited company based in Thane, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 February 2020 (6+ years old) and is registered under CIN U74999MH2020PTC337046.
Reflux Pharmaceuticals reported revenue of ₹20.56 Cr for FY 2025 (up 15% YoY).
Reflux Pharmaceuticals has 3 current directors:
- Jaid Ismail Kojar - Nominee Director
- Amit Kumar Ghosh - Director
- Sandeep Khandu Tekle - Director
Reflux Pharmaceuticals reported a net profit of ₹57.3 Lakh (net margin 2.8%) and EBITDA of ₹98.01 Lakh (EBITDA margin 4.8%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Reflux Pharmaceuticals is 5% over three years. In the latest year (FY 2025) revenue rose 15%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Reflux Pharmaceuticals is 27AAKCR0622C1ZR, registered in Maharashtra.
The CIN (Corporate Identification Number) of Reflux Pharmaceuticals is U74999MH2020PTC337046. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Reflux Pharmaceuticals was incorporated on 03 February 2020, making it 6+ years old. It is registered with the Registrar of Companies, Mumbai.
Reflux Pharmaceuticals has 1 deal on record (1 funding round), with disclosed funding of ₹7.01 Cr; the latest was in May 2023.
The peers of Reflux Pharmaceuticals by revenue are SBD Healthcare Private Limited, Essel Pharmaceuticals Private Limited, Medinex Laboratories Private Limited, Bhattacharjee Pharmaceuticals and Company Ltd, Medizest Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (API Manufacturers, Pharmaceuticals).
Jaid Ismail Kojar was appointed as Nominee Director on 29 Jul 2024. Amit Kumar Ghosh was appointed as Director on 03 Feb 2020. Sandeep Khandu Tekle was appointed as Director on 03 Feb 2020.
Reflux Pharmaceuticals has 4 MSME Form 1 returns on record between 2022 and 2023, listing 16 overdue payments to 4 micro and small suppliers. The latest return was filed on 30 Aug 2023.